Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Single-Cell RNA Sequencing Reveals Shenbai Granule Retards Colorectal Tumorigenesis by Modulating Cholesterol-Induced Ccl22+ DCs and Tregs Crosstalk

ABSTRACT: Colorectal tumorigenesis generally follows a progressive sequence from adenoma to adenocarcinoma, accompanied by dynamic changes in the tumor microenvironment (TME). Randomized controlled trials have confirmed that Shenbai Granule (SBG), a traditional Chinese medicine formula, is safe and effective for the prevention of recurrent colorectal adenoma. However, the effects and mechanisms of SBG on colorectal tumorigenesis and the TME remain unclear. To investigate this, single-cell RNA sequencing (scRNA-seq) was conducted to reveal the dynamic evolution of the TME. Primary cells were isolated for in vitro validation experiments. The findings demonstrated that SBG reduces both the number and volume of tumors. There was a marked accumulation of Ccl22+ dendritic cells (DCs) and an enhanced interaction between Ccl22+ DCs and CD4+ regulatory T cells (Tregs), which were reversed by the treatment of SBG and its active compound, berberine. Combined treatment with cholesterol and lipopolysaccharide induced characteristic gene expression in Ccl22+ DCs, which may represent a type of “exhausted DCs”. Intraperitoneal injection of the Ccl22+ DCs after SBG treatment eliminated its therapeutic effects. These findings highlight critical crosstalk between Ccl22+ DCs and CD4+ Tregs in colorectal cancer. The multi-component properties of natural products may restore TME homeostasis and offer novel cancer therapy.

ORGANISM(S): Mus musculus Homo sapiens

PROVIDER: GSE277268 | GEO | 2025/07/30

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Single-Cell RNA Sequencing Reveals Shenbai Granule Retards Colorectal Tumorigenesis by Modulating Cholesterol-Induced Ccl22+ DCs and Tregs Crosstalk

Project description:Single-Cell RNA Sequencing Reveals Shenbai Granule Retards Colorectal Tumorigenesis by Modulating Cholesterol-Induced Ccl22+ DCs and Tregs Crosstalk

| PRJNA1161624 | ENA

CCL22 mutations in chronic lymphoproliferative disorder of NK cells (CLPD-NK)

Project description:We engrafted empty vector, wild type CCL22, and Pro79Arg-CCL22 mutant-expressing NK-92 cells into NOD.Cg-Prkdcscid Il2rgtm1Wjl Tg(IL15)1Sz/SzJ mice to assess in vivo function of detected CCL22 mutations. Engrafted Pro79Arg NK-92 cells recapitulated the phenotype of CLPD-NK patients with CCL22 mutations.

2022-01-19 | GSE163864 | GEO

Targeting an immunoregulatory dendritic cell-CCL22 program alleviates radioresistance

Project description:Purpose: Radiation-mediated immune suppression limits efficacy and is a barrier in cancer therapy. Radiation induces negative regulators of tumor immunity including regulatory T cells (Treg). Mechanisms underlying Treg infiltration after radiotherapy (RT) are poorly defined. Given that dendritic cells (cDC) maintain Treg we sought to identify and target cDC signaling to block Treg infiltration after radiation. Experimental Design: Transcriptomics and high dimensional flow cytometry revealed changes in murine tumor cDC that not only mediate Treg infiltration after RT, but associate with worse survival in human cancer datasets. Antibodies perturbing a cDC-CCL22-Treg axis were tested in syngeneic murine tumors. A prototype interferon-anti-epidermal growth factor receptor fusion protein (αEGFR-IFNα) was examined to block Treg infiltration and promote a CD8+ T cell response after RT. Results: Radiation expands a population of mature cDC1 enriched in immunoregulatory markers that mediates Treg infiltration via the Treg-recruiting chemokine CCL22. Blocking CCL22 or Treg depletion both enhanced RT efficacy. αEGFR-IFNα blocked cDC1 CCL22 production while simultaneously inducing an antitumor CD8+ T cell response to enhance RT efficacy in multiple EGFR-expressing murine tumor models, including following systemic administration. Conclusions: We identify a previously unappreciated cDC mechanism mediating Treg tumor infiltration after RT. Our findings suggest blocking the cDC1-CCL22-Treg axis augments RT efficacy. αEGFR-IFNα added to RT provided robust antitumor responses better than systemic free interferon administration, and may overcome clinical limitations to interferon therapy. Our findings highlight the complex behavior of cDC after RT and provide novel therapeutic strategies for overcoming RT-driven immunosuppression to improve RT efficacy.

2024-04-17 | GSE262864 | GEO

gene expression of KYSE410 cells with control or treatment of 50 ng/mL CCL22

Project description:KYSE410 cells were treated with 50 ng/mL CCL22, and KYSE410 cells were collected for gene expression analysis using Agilent SurePrint G3 Human Gene Expression v3 (8×60K) Microarray. Investigation of the critical gene of KYSE410 cells treated by 50 ng/mL CCL22.

2025-05-05 | GSE202343 | GEO

Regulatory T cells in the Tumor Microenvironment Display a Unique Chromatin Accessibility Profile (RNA-Seq)

Project description:Regulatory T cells (Tregs) are a suppressive CD4+ T cell population that limit the anti-tumor immune response. In this study, we analyzed the chromatin accessibility of Tregs in the murine tumor microenvironment (TME) to identify tumor-specific accessible peaks and if these are altered over time in the tumor microenvironment, with or without anti-PD1 immunotherapy. We found that Tregs have a more distinct chromatin accessibility signature in the TME compared to Tregs in the periphery than within location over time in the models we accessed. This distinct tumor Treg chromatin accessibility profile highlights reduced accessibility at loci important for an CD4+ conventional T cell (CD4+ Foxp3—) effector phenotype and reinforcement of a suppressive phenotype. Analysis of chromatin accessibility in Tregs in B16 and MC38 tumor models indicated similar regulation independent of tumor type, indicating a tumor-derived Treg effector signature in the models we accessed. We also found that Tregs do not alter their transcriptome nor chromatin accessibility following immunotherapy. We conclude that chromatin accessibility in Tregs is altered in the TME, but is otherwise remarkably stable and appears unaltered by tumor type, over time, or following immunotherapy.

2025-02-26 | GSE246701 | GEO

Regulatory T cells in the Tumor Microenvironment Display a Unique Chromatin Accessibility Profile (ATAC-Seq)

2025-02-26 | GSE246700 | GEO

Pairwise comparison of ST2+ and ST2- FOXP3+ T cells derived from mouse intestinal tumors

Project description:Colorectal cancer (CRC) was induced in Foxp3/eGFP reporter mice by the azoxymethane/dextran sulphate sodium salt (AOM/DSS) protocol. Mice were injected i.p. with the procarcinogen AOM (12.5 mg/kg of body weight). After 1 week, mice received drinking water supplemented with 2.5% DSS for 5 to 7 days, followed by 2 weeks of regular water. The DSS administration was repeated twice with 2% DSS. Mice were sacrificed at week 11 and lamina propia lymphocytes (LPLs) from the colon were isolated. CD4+FOXP3+ (eGFP+) ST2+ or ST2- Tregs were separated from colonic LPLs of CRC induced mice using a FACSAria II cell sorter. Microarray analysis was performed to analyze if ST2+ FOXP3+ Tregs from the colon of CRC mice present a distinct transcription pattern compared to ST2- FOXP3+ Tregs. By this, the role of ST2 for Treg function during intestinal tumorigenesis should be characterized.

2019-05-31 | E-MTAB-6842 | biostudies-arrayexpress

Tumor-Infiltrating Regulatory T Cell Accumulation in the Tumor Microenvironment is Mediated by IL33/ST2 Signaling

Project description:Regulatory T cells (Tregs) are enriched in the tumor microenvironment (TME) and suppress anti-tumor immunity. However, the origin of tumor-infiltrating (TI) Tregs and the molecular mechanism underlying their TME accumulation are poorly understood. Although IL-33 was reported to regulate the expansion and function of Tregs, its direct role on TI Tregs and its contribution to tumor progression remain uncertain. Firstly, we demonstrated TI Tregs were primarily thymus-derived. More importantly, we found using comparative transcriptome analysis that proliferation-related genes were prominently upregulated in TI Tregs compared with TI CD4+Foxp3− conventional T cells or splenic Tregs of same tumor-bearing mice. One of these genes, ST2, an interleukin-33 (IL-33) receptor, was identified as a potential factor driving Treg accumulation in the TME. Indeed, IL-33-directed ST2 signaling induced the preferential proliferation of TI Tregs and enhanced tumor progression, while genetic deletion of ST2 in Tregs limited their TME accumulation and delayed tumor growth. These data demonstrate the IL-33/ST2 axis in Tregs as one of the critical pathways for the preferential accumulation of thymus-derived Tregs in the TME and suggest the axis as a potential therapeutic target for cancer immunotherapy.

2020-08-12 | GSE152022 | GEO

CCL22 chemokine mutations drive natural killer cell lymphoproliferative disease by biasing GPCR signaling

Project description:Chronic lymphoproliferative disorder of natural killer cells (CLPD-NK) is characterized by clonal expansion of NK cells of incompletely understood genomic basis. Here, we report somatic mutations in the chemokine gene CCL22 as the hallmark of a distinct subset of CLPD-NK. CCL22 mutations were enriched at highly conserved residues, were mutually exclusive of STAT3 mutations, and were associated with gene expression similar to normal CD16dim/CD56bright NK cells. Mechanistically, the mutations resulted in ligand-biased chemokine receptor signaling, with decreased internalization of the G-protein-coupled receptor for CCL22, CCR4, via impaired ÃŽÂ²-arrestin recruitment. This resulted in increased cell chemotaxis in vitro, bidirectional crosstalk with the hematopoietic microenvironment, and enhanced NK cell proliferation in vivo in transgenic human IL-15 mice. Somatic CCL22 mutations illustrate a novel mechanism of tumor formation in which gain-of-function chemokine mutations promote tumorigenesis by biased G-protein-coupled receptor signaling and dysregulation of microenvironmental crosstalk.

| EGAS00001006009 | EGA

Targeting an immunoregulatory dendritic cell-CCL22 program alleviates radioresistance

Project description:Targeting an immunoregulatory dendritic cell-CCL22 program alleviates radioresistance

| PRJNA1094396 | ENA